Table 1.
Clinical gastroenteritis and risk of inflammatory bowel disease.
| Study | Study location and Period | Study Design | Study population | Patient-years or years of follow up | Number of exposed individuals | GE Diagnosis | Number of IBD diagnoses | Risk Assessment (95% CI) |
|---|---|---|---|---|---|---|---|---|
| Garcia Rodriguez, 200616 | UK, 1992–2001 | Cohort | General Practice Research Database in UK 94,013 |
325,743 | 43,013 (All GE) | ICD coding | 64 (UC) | UC: HR 2.3 (1.5–3.6; All GE) |
| Porter 200814 | USA, 1999–2006 | Case-control | US military 14,665 |
Max 7 years per patient | 828 (All GE) | ICD coding | 115 (UC) | UC: OR 1.4 (1.1–1.7; All GE) |
| Gradel, 200911 | Denmark, 1991–2003 | Cohort | Nationwide 39,264 |
Max 15 years per patient | 6,685 (Campylobacter) | ICD coding | 79 (UC) | UC: HR 2.8 (1.7–4.6; Salmonella) |
| Jess, 201117 | Denmark, 1992–2008 | Cohort | Nationwide NR |
94,264,447 | 49,420 (Campylobacter) | Stool culture | 487 (UC) | UC: IRR 3.0 (2.6–3.4; Salmonella) |
| Porter, 201715 | USA, 2001–2009 | Cohort | US military 82,107 |
470,060 | 18 (All GE, in IBD only) | ICD coding | 49 (UC) | UC: HR 2.9 (1.4–6.0; All GE) |
| Castaño-Rodríguez, 201713 | Pooled | Meta-analysis | Pooled, 1652 | - | - | - | 519 (IBD) | IBD: P-OR 2.97 (1.33 to 6.63, |
| Axelrad, 201918 | Sweden, 2002–2014 | Case-control | Nationwide 480,721 |
Max 12 years per patient | 20,790 (All GE) | ICD coding | 1,672 (UC) | UC: OR 1.6 (1.5–1.7; All GE) |
IBD: Inflammatory bowel disease; UC: ulcerative colitis; CD: Crohn’s disease; IBD-U: Inflammatory bowel disease- Unclassified; GE: gastroenteritis; HR: hazard ratio; OR: odds ratio; IRR: incidence rate ratio; NR: not reported; CI: confidence interval